Yiming Zhang

Guangdong Provincial Key Laboratory Of Speed Capability, The Guangzhou Key Laboratory Of Precision Orthopedics And Regenerative Medicine
Guangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Pericyte NNMT drives an immune-hostile vascular niche and restricts cancer immunotherapy.

Pericyte NNMT drives an immune-hostile vascular niche and restricts cancer immunotherapy.

Journal: Science bulletin

Published: August 28, 2025

CCCTC-binding factor regulates splicing factor proline and glutamine-rich to promote malignant growth of osteosarcoma.

CCCTC-binding factor regulates splicing factor proline and glutamine-rich to promote malignant growth of osteosarcoma.

Journal: American journal of translational research

Published: December 26, 2024

APOE suppresses osteosarcoma by modulating ferroptosis through the mTOR/Stat3 signaling pathway.

APOE suppresses osteosarcoma by modulating ferroptosis through the mTOR/Stat3 signaling pathway.

Journal: Archives of medical science : AMS

Published: September 27, 2024

HSPD1 Supports Osteosarcoma Progression through Stabilizing ATP5A1 and thus Activation of AKT/mTOR Signaling.

HSPD1 Supports Osteosarcoma Progression through Stabilizing ATP5A1 and thus Activation of AKT/mTOR Signaling.

Journal: International journal of biological sciences

Published: June 24, 2024

Basement membrane-associated gene P3H2 regulates osteosarcoma progression and epithelial-mesenchymal transition through AKT/mTOR signaling axis.

Basement membrane-associated gene P3H2 regulates osteosarcoma progression and epithelial-mesenchymal transition through AKT/mTOR signaling axis.

Journal: Translational oncology

Published: May 25, 2024

Identification of UNC5B as a novel aggressive biomarker for osteosarcoma based on basement membrane genes.

Identification of UNC5B as a novel aggressive biomarker for osteosarcoma based on basement membrane genes.

Journal: Gene

Published: April 26, 2024

Oncogenic and immunological values of RBM34 in osteosarcoma and its pan-cancer analysis.

Oncogenic and immunological values of RBM34 in osteosarcoma and its pan-cancer analysis.

Journal: American journal of cancer research

Published: September 29, 2023

The role of mitochondria-related lncRNAs in characterizing the immune landscape and supervising the prognosis of osteosarcoma.

The role of mitochondria-related lncRNAs in characterizing the immune landscape and supervising the prognosis of osteosarcoma.

Journal: Journal of bone oncology

Published: May 30, 2023

The splicing factor proline and glutamine rich promotes the growth of osteosarcoma via the c-Myc signaling pathway.

The splicing factor proline and glutamine rich promotes the growth of osteosarcoma via the c-Myc signaling pathway.

Journal: American journal of cancer research

Published: March 16, 2023

Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma.

Comprehensive multi-omics analysis reveals m7G-related signature for evaluating prognosis and immunotherapy efficacy in osteosarcoma.

Journal: Journal of bone oncology

Published: February 20, 2023

miR-1297 inhibits osteosarcoma cell proliferation and growth by targeting CCND2.

miR-1297 inhibits osteosarcoma cell proliferation and growth by targeting CCND2.

Journal: American journal of cancer research

Published: June 06, 2022

CircNRIP1 acts as a sponge of miR-1200 to suppress osteosarcoma progression via upregulation of MIA2.

CircNRIP1 acts as a sponge of miR-1200 to suppress osteosarcoma progression via upregulation of MIA2.

Journal: American journal of cancer research

Published: April 30, 2022

Showing 1-12 of 20

Last Updated: 09/26/2026